share_log

Sigilon Therapeutics (NASDAQ:SGTX) Trading Down 0.6%

Sigilon Therapeutics (NASDAQ:SGTX) Trading Down 0.6%

Sigilon Therapeutics(纳斯达克股票代码:SGTX)交易下跌0.6%
Defense World ·  2023/03/29 13:53

Sigilon Therapeutics, Inc. (NASDAQ:SGTX – Get Rating) shares were down 0.6% on Tuesday . The stock traded as low as $0.93 and last traded at $0.93. Approximately 28,516 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 429,872 shares. The stock had previously closed at $0.94.

周二,Sigilon Therapeutics, Inc.(纳斯达克股票代码:SGTX — 获取评级)股价下跌0.6%。该股的交易价格低至0.93美元,最后一次交易价格为0.93美元。午盘交易中约交易了28,516股,较平均每日交易量429,872股下降了93%。该股此前收于0.94美元。

Wall Street Analyst Weigh In

华尔街分析师权衡一下

Separately, Canaccord Genuity Group started coverage on Sigilon Therapeutics in a report on Wednesday, January 18th. They issued a "buy" rating and a $6.00 price objective for the company.

另外,Canaccord Genuity Group在1月18日星期三的一份报告中开始报道Sigilon Therapeutics。他们为该公司发布了 “买入” 评级和6.00美元的目标价格。

Get
获取
Sigilon Therapeutics
西吉隆疗法
alerts:
警报:

Sigilon Therapeutics Stock Down 0.6 %

Sigilon Therapeutics股票下跌0.6%

The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.31. The firm has a market cap of $30.20 million, a PE ratio of -0.69 and a beta of 0.86. The stock has a fifty day simple moving average of $0.87 and a two-hundred day simple moving average of $0.60.

该公司的流动比率为2.40,速动比率为2.40,债务与权益比率为0.31。该公司的市值为3020万美元,市盈率为-0.69,beta值为0.86。该股的五十天简单移动平均线为0.87美元,两百天简单移动平均线为0.60美元。

Institutional Inflows and Outflows

机构流入和流出

A number of hedge funds have recently added to or reduced their stakes in SGTX. Millennium Management LLC purchased a new position in Sigilon Therapeutics during the 2nd quarter valued at about $256,000. Renaissance Technologies LLC grew its holdings in Sigilon Therapeutics by 131.8% during the 1st quarter. Renaissance Technologies LLC now owns 275,600 shares of the company's stock valued at $405,000 after buying an additional 156,689 shares in the last quarter. State Street Corp grew its holdings in Sigilon Therapeutics by 26.7% during the 1st quarter. State Street Corp now owns 330,471 shares of the company's stock valued at $486,000 after buying an additional 69,662 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Sigilon Therapeutics by 22.3% during the 3rd quarter. Vanguard Group Inc. now owns 300,912 shares of the company's stock valued at $152,000 after buying an additional 54,770 shares in the last quarter. Hedge funds and other institutional investors own 52.20% of the company's stock.

一些对冲基金最近增加了或减少了在SGTX的股份。Millennium Management LLC在第二季度收购了Sigilon Therapeutics的新头寸,价值约为25.6万美元。文艺复兴科技有限责任公司在第一季度将其在Sigilon Therapeutics的持股量增加了131.8%。Renaissance Technologies LLC在上个季度又购买了156,689股股票后,现在拥有该公司275,600股股票,价值40.5万美元。State Street Corp在第一季度将其在Sigilon Therapeutics的持股量增加了26.7%。State Street Corp在上个季度又购买了69,662股股票后,现在拥有该公司330,471股股票,价值48.6万美元。最后,Vanguard Group Inc.在第三季度将其在Sigilon Therapeutics的持股量增加了22.3%。Vanguard Group Inc.在上个季度又购买了54,770股股票后,现在拥有该公司300,912股股票,价值15.2万美元。对冲基金和其他机构投资者拥有该公司52.20%的股票。

About Sigilon Therapeutics

Sigilon Therapeutics

(Get Rating)

(获取评级)

Sigilon Therapeutics, Inc, a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes.

Sigilon Therapeutics, Inc是一家临床阶段的生物技术公司,为慢性病患者开发功能性疗法。其主要候选产品是 SIG-001,它正处于 I/II 期临床试验,旨在预防中度至重度 A 型血友病患者出血发作。该公司还在开发 SIG-005 来治疗 1 型粘多糖增多症的非神经系统表现;SIG-007 用于持续和长时间释放功能酶,其水平足以产生临床益处和缓解 Fabry 病下游方面的进展;以及用于取代胰岛细胞治疗 1 型糖尿病的 SIG-002。

Featured Articles

精选文章

  • Get a free copy of the StockNews.com research report on Sigilon Therapeutics (SGTX)
  • After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
  • Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
  • Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
  • The Bottom Is In For McCormick & Company
  • Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
  • 免费获取 StockNews.com 关于 Sigilon Therapeutics (SGTX) 的研究报告的副本
  • 在收益井喷之后,Ciena 股票是买入机会吗?
  • 这就是为什么Viking Therapeutics根据肥胖药物数据上涨了50%以上的原因
  • Meta 突破了基础,看起来又像成长型股票了
  • McCormick & Company 已经触底了
  • Walgreens Boots Alliance:蓝筹股、高收益转型故事

Receive News & Ratings for Sigilon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigilon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

每天接收 Sigilon Therapeutics 的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Sigilon Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发